PT - JOURNAL ARTICLE AU - Mazzeo, Salvatore AU - Lassi, Michael AU - Padiglioni, Sonia AU - Vergani, Alberto Arturo AU - Moschini, Valentina AU - Scarpino, Maenia AU - Giacomucci, Giulia AU - Burali, Rachele AU - Morinelli, Carmen AU - Fabbiani, Carlo AU - Galdo, Giulia AU - Bagnoli, Silvia AU - Emiliani, Filippo AU - Ingannato, Assunta AU - Nacmias, Benedetta AU - Sorbi, Sandro AU - Grippo, Antonello AU - Mazzoni, Alberto AU - Bessi, Valentina TI - PRedicting the EVolution of SubjectIvE Cognitive Decline to Alzheimer’s Disease With machine learning: the PREVIEW study protocol AID - 10.1101/2023.04.15.23288619 DP - 2023 Jan 01 TA - medRxiv PG - 2023.04.15.23288619 4099 - http://medrxiv.org/content/early/2023/04/19/2023.04.15.23288619.short 4100 - http://medrxiv.org/content/early/2023/04/19/2023.04.15.23288619.full AB - Background and aims Subjective Cognitive Decline (SCD) is a condition in which individual complain of cognitive decline with normal performances on neuropsychological evaluation. Many studies demonstrated a higher prevalence of Alzheimer’s pathology in patients diagnosed with SCD as compared to the general population. Consequently, SCD was suggested as an early symptomatic phase of Alzheimer’s disease (AD). We will describe the study protocol of a prospective cohort study (PREVIEW) that aim to identify features and tools to accurately detect SCD patients who will progress to AD.Methods We will include patients self-referred to our memory clinic and diagnosed with SCD. Participants will undergo: clinical, neurologic and neuropsychological examination, estimation of cognitive reserve and depression, evaluation of personality traits, APOE and BDNF genotyping, electroencephalography and event-related potential recording, lumbar puncture for measurement of Aβ42, t-tau, and p-tau concentration and Aβ42/Aβ40 ratio. Recruited patients will have follow-up neuropsychological examination every two years. Collected data will be used to train a machine learning algorithm to define the risk of progression from SCD to MCI and AD.Discussion There is an urgent need to select cost-effective and easily accessible tools to identify patients at the earliest stages of the disease. Previous studies identified demographic, cognitive, genetic, neurophysiological and brain structure features to stratify SCD patients according to the risk of progression to objective cognitive decline. Nevertheless, only a few studies considered all these features together and applied machine learning approaches on SCD patients.Conclusions the PREVIEW study aim to identify new cost-effective disease biomarkers (e.g., EEG-derived biomarkers) and define automated algorithm to detect patients at risk for AD in a very early stage of the disease.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05569083Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT05569083 Funding StatementThis project is funded by Tuscany Region - PRedicting the EVolution of SubjectIvE Cognitive Decline to Alzheimer's Disease With machine learning - PREVIEW - CUP. D18D20001300002Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All subjects will be recruited in accordance with the Declaration of Helsinki and with the ethical standards of the Committee on Human Experimentation of Careggi University Hospital (Florence, Italy). The study was approved by the local Institutional Review Board (reference 15691oss). All participants in this study will sign an informed consent, agreeing to participate and to share the results deriving from their data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData derived from this study will be available from the corresponding author upon reasonable request.